BioNTech Stock Slips Despite Q4 Beats
German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...
The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.
Stocktwits on MSN2d
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously OptimisticU.S.-listed shares of BioNTech SE ended Monday nearly 3.2% lower, weighed down by a weak full-year revenue projection even as ...
TD Cowen lowered the firm’s price target on BioNTech (BNTX) to $110 from $122 and keeps a Hold rating on the shares. The firm updated its model ...
Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...
The company's net profit per share, which was €3.83 in 2023, turned into a loss of €2.77 in 2024. The German company is ...
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .
BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...
German biotech company BioNTech announced a financial loss of €665.3 million ($721 million) for 2024, attributing the decline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback